Response Pharmaceuticals
Targeted Solutions for Weight Management and Metabolic Health
About
Response Pharmaceuticals is developing its lead asset, RDX-002, a first-in-class weight management and cardiometabolic health drug with confirmed efficacy and safety in >550 subjects. All programs are in Phase 2 clinical development. Our initial focus is on helping underserved patient populations taking antipsychotic medications for disabling mental illnesses to combat weight gain and metabolic dysregulation associated with these treatments. Antipsychotic-induced weight gain (AIWG) is a drug-induced epidemic within the already vulnerable population of patients with severe mental illness, and is contributing to a growing mortality gap between people with mental illness and the general population. Additionally, RDX-002 is being evaluated in other settings in which clinically significant weight gain and/or adverse metabolic changes are prevalent.
Product
- Value proposition
- Developing RDX-002, a novel small-molecule iMTP inhibitor, to support weight management, including post-GLP-1 receptor agonist patients and antipsychotic-induced weight gain.
Founders
- Eric Keller — CEO, Founder & Chairman
- Paul Sweetnam — CSO & Co-Founder
Categories
Products
Key features
Technologies
Target conditions
Care settings
News
- Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management · 2026-03-05T00:00:00.000Z
- Response Pharma’s Novel Pill for Weight Loss Shows Promise as Post-GLP-1 Maintenance Therapy - MedCity News · 2025-08-13T23:20:27.000Z
- Response Pharmaceuticals to Present Data on RDX-002 in Antipsychotic-Induced Weight Gain at the 2026 American Psychiatric Association Annual Meeting · 2026-05-12T00:00:00.000Z
- Response Pharmaceuticals Announces Positive Top-Line Results From Phase 2 Study of RDX-002 in Post-GLP-1 Management - BioSpace · 2025-08-14T06:16:21.000Z
- Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management - BioSpace · 2026-03-05T14:30:15.000Z
- Response Pharmaceuticals Announces Early Completion of Enrollment of a Phase 2 Study Evaluating RDX-002 Treating Patients Discontinuing GLP-1 Agonists · 2025-02-06T13:00:00.000Z
More links
Browse similar startups
Related startups
- Richmond Heart and Vascular Associates — Mechanicsville, VA
- RICHMOND PEDIATRIC ASSOCIATES INC — Varina, VA
- SalivIQ Diagnostics, Inc. — Harrisonburg, VA
- SHENANDOAH ORAL AND FACIAL SURGERY, PLC — Rockingham, VA
- TNM- Radiation Oncology Solutions — McLean, VA
- Tralyte Health — Richmond, VA
- Riboway Therapeutics — Cambridge, MA
- Sarcomatrix — Reno, NV
- Senvera Therapeutics, Inc. A Curie.Bio Company — Boston, MA
- Stipple Bio — Cambridge, MA
- Symbiome — San Francisco, CA
- Synamics Therapeutics — Beverly Hills, CA
Profile updated Jul 29, 2026. Sources: responsepharmaceuticals.com, linkedin.com
